Helix BioPharma (TSX: HBP), an integrated biopharmaceutical company focused on the discovery and development of innovative anti-cancer therapeutics, today announced that Chief Financial Officer Leslie Auld is leaving the Company to pursue a senior finance position with another company. Helix is currently in the process of identifying candidates to replace Ms. Auld. Kenneth Cawkell, a director of Helix and the Corporate Secretary will act as interim CFO until the Company locates a suitable replacement.
